Fast Market Research

"Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015" Now Available at Fast Market Research

Fast Market Research announces the availability of the new Global Markets Direct report, "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/12/2016 -- Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: AbbVie Inc., Actelion Ltd, Actinium Pharmaceuticals, Inc., Actinogen Limited, Activartis Biotech GmbH, Aduro BioTech, Inc., Advanced Accelerator Applications SA, Advanced Cancer Therapeutics, Advenchen Laboratories, LLC, Agenus, Inc., Amal Therapeutics SA, Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., AngioChem Inc., APIM Therapeutics AS, Apogenix GmbH, Argon Pharma S.L., Ariad Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, Axelar AB, BeiGene(Beijing) Co.,Ltd, Bexion Pharmaceuticals, LLC., Bioasis Technologies Inc., BioCancell Ltd, Biomar Microbial Technologies, Bioncotech Therapeutics S.L., Biovista Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Caladrius Biosciences, Inc., CalAsia Pharmaceuticals, Inc., Cavion LLC, Celgene Corporation, Celldex Therapeutics, Inc., Cellectis S.A., Celltrion, Inc., Celsion Corporation, Champions Oncology, Inc., ChemoCentryx, Inc., CLL Pharma, CTI BioPharma Corp., CureFAKtor Pharmaceuticals, LLC, CytomX Therapeutics, Inc., CytoVac A/S, CytRx Corporation, Deciphera Pharmaceuticals, LLC, DEKK-TEC, Inc., Delenex Therapeutics AG, Diffusion Pharmaceuticals LLC, DiscoveryBiomed, Inc., Dr. Reddy's Laboratories Limited, e-Therapeutics Plc, Ecrins Therapeutics SAS, EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, EnGeneIC Ltd, EntreChem, S.L., Epirus Biopharmaceuticals, Inc., ERC Belgium SA, Evotec AG, Exelixis, Inc., F. Hoffmann-La Roche Ltd., FirstString Research, Inc., Five Prime Therapeutics, Inc., Galileo Research s.r.l., Genentech, Inc., Genor BioPharma Co., Ltd., GenSpera, Inc., Genzyme Corporation, GlaxoSmithKline Plc, GW Pharmaceuticals Plc, HEC Pharm Co., Ltd., Hospira, Inc., immatics biotechnologies GmbH, ImmunoCellular Therapeutics, Ltd., Immunocore Limited, Immunomic Therapeutics, Inc., Immunovaccine, Inc., Infinity Pharmaceuticals, Inc., INSYS Therapeutics, Inc., InteRNA Technologies B.V., Intica Biomedical, Inc., Jiangsu Kanion Pharmaceutical Co., Ltd., Johnson & Johnson, Kadmon Corporation, LLC, Kalgene Pharmaceuticals Inc., KaloBios Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Kite Pharma, Inc., Komipharm International Co., Ltd., Lentigen Technology, Inc., Les Laboratoires Servier SAS, LinXis B.V., Lixte Biotechnology Holdings, Inc., Loxo Oncology, Inc., Mabion SA, Medicenna Therapeutics, Inc, MedImmune, LLC, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Mycenax Biotech Inc., Nascent Biotech, Inc., Nemucore Medical Innovations, Inc., Nerviano Medical Sciences S.r.l., Neuralstem, Inc., NewLink Genetics Corporation, Nexgenix Pharmaceuticals, LLC, Northwest Biotherapeutics, Inc., Novartis AG, Novogen Limited, Noxxon Pharma AG, Omniox, Inc., Oncobiologics, Inc., Oncodesign SA, Oncolytics Biotech Inc., Onconova Therapeutics, Inc., Ono Pharmaceutical Co., Ltd., Orphagen Pharmaceuticals, Inc., Oryx GmbH & Co. KG, OXiGENE, Inc., Panacea Biotec Limited, Panacela Labs, Inc., Peloton Therapeutics, Inc., Peregrine Pharmaceuticals, Inc., Pfizer Inc., PharmAbcine, Inc., PharmaCyte Biotech, Inc., Plexxikon Inc., Prana Biotechnology Limited, Progenics Pharmaceuticals, Inc., Regulus Therapeutics Inc., RestorGenex Corporation, Rexahn Pharmaceuticals, Inc., Rigontec GmbH, Sagetis Biotech, S.L., Sanofi, Selvita SA, Siena Biotech S.p.A., Sigma-Tau S.p.A., Sirnaomics, Inc., Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., STELIS Biopharma Pvt. Ltd., Stemline Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, Susavion Biosciences, Inc., Terpenoid Therapeutics, Inc., Therapeia GmbH & Co. KG, Theravectys SA, Threshold Pharmaceuticals, Inc., Tocagen Inc., TRACON Pharmaceuticals, Inc., TVAX Biomedical, Inc., Upsher-Smith Laboratories, Inc., Vascular Biogenics Ltd., VBI Vaccines Inc., Vertex Pharmaceuticals Incorporated, ViraTherapeutics GmbH, Virttu Biologics Limited, ZIOPHARM Oncology, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015
-Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
-Brain Cancer - Pipeline Review, H2 2015
-Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015
-Hepatitis C - Pipeline Review, H2 2015